A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)

Prior treatment

• Active chronic (or stable but treated with immune therapy) disease of the immune system other than MG (e.g., rheumatoid arthritis, scleroderma, Sjögren's syndrome, Crohn's disease, ulcerative colitis, etc.) or immunodeficiency syndrome (hereditary immune deficiency, drug-induced immune deficiency, etc.).
• Lack of efficacy or observed safety concerns from prior neonatal Fc receptor (FcRn) treatment.
• Prior treatment with B-cell depleting therapy, alemtuzumab, total lymphoid irradiation, bone marrow transplant, T-cell vaccination therapy, or natalizumab at any time prior to screening.

Other illness

• History of life-threatening injection/infusion related reaction (IRR/ISR), hypersensitivity, or anaphylactic reaction with components of efgartigimod or ublituximab solutions, protocol-allowed rescue medications, or protocol required pre-treatment medications.

Other

• Participants with significantly impaired organ function.
• Unwillingness or inability to comply with study and/or follow-up procedures outlined in the protocol.
  • Note: Other protocol-specified Inclusion/Exclusion criteria may apply.

• Documentation of MG diagnosis.
• Eligible for treatment with efgartigimod per effective local product label, confirmed by serological testing at screening.
• MG-ADL score at the time of screening more than or equal to (≥) 6 and less than or equal to (≤) 10 with more than (\>) 50 percent (%) of this score attributed to non-ocular items, or an MG-ADL score ≥ 11.